Free tool
FAERS Monitor: Epclusa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214187 or its brand name (Epclusa, Sofosbuvir, Velpatasvir). Reports on generic versions are filed under their own applications.
Reports
12,567
Serious
3,745
30% of reports
Hospitalization
1,368
Death reported
566
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue2,600
- headache2,201
- nausea1,163
- diarrhoea650
- drug ineffective549
- insomnia508
- hepatitis c410
- treatment failure334
- vomiting324
- death291
- dizziness282
- rash255
- product dose omission issue246
- abdominal discomfort234
- intentional dose omission215
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 400 |
| 2017 | 2,137 |
| 2018 | 2,222 |
| 2019 | 2,661 |
| 2020 | 1,692 |
| 2021 | 1,021 |
| 2022 | 934 |
| 2023 | 540 |
| 2024 | 407 |
| 2025 | 345 |
| 2026 | 208 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,592 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatitis cSignal | 410 | 58.8 | 53.4 | 22,462 |
| intentional dose omissionSignal | 215 | 12.7 | 11.1 | 2,293 |
| treatment failureSignal | 334 | 6.8 | 6.1 | 1,637 |
| headacheSignal | 2,201 | 5.9 | 5.7 | 9,179 |
| fatigueSignal | 2,600 | 5.6 | 5.4 | 10,175 |
| insomniaSignal | 508 | 3.2 | 2.9 | 773 |
| nauseaSignal | 1,163 | 2.5 | 2.3 | 1,046 |
| abdominal discomfortSignal | 234 | 2.3 | 2.1 | 179 |
| diarrhoea | 650 | 1.7 | 1.6 | 186 |
| product dose omission issue | 246 | 1.4 | 1.2 | 28 |
| vomiting | 324 | 1.2 | 1.0 | 7 |
| rash | 255 | 1.0 | 0.9 | 0 |
| dizziness | 282 | 0.9 | 0.8 | 1 |
| drug ineffective | 549 | 0.7 | 0.6 | 77 |
| death | 291 | 0.6 | 0.5 | 101 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.